Sofinnova Investments related stories
All articles and analysis
VC-backed Aerie Pharmaceuticals hires marketing directorAerie Pharmaceuticals, a developer of drugs that treat glaucoma patients, has named Nina Ohara as director of marketing.
Intrepida Bio attracts $9.5 mlnSan Diego-based Intrepida Bio Inc, a newly launched drug developer, has secured $9.5 million in funding. The investors were Sofinnova Investments and Canaan.
- CinCor Pharma picks up $50 mln Series A
CinCor Pharma, a biopharmaceutical company, has secured $50 million in Series A funding. Sofinnova Investments led the round.
- VC-backed NextCure rolls out IPO
NextCure Inc, a biopharmaceutical company focused on treating cancer, has raised $75 million for its IPO after pricing its 5 million shares at $15 per share. The stock began trading May 9, 2019 on the NASDAQ under the ticker symbol "NXTC." Morgan Stanley, BofA Merrill Lynch and Piper Jaffray & Co are the lead underwriters. NextCure's pre-IPO backers included OrbiMed, Sofinnova Investments, Hillhouse Capital and Lilly Asia Ventures.
- Sofinnova hires Maha Katabi as partner, will open Montréal office
Silicon Valley biotechnology investment firm Sofinnova Investments has hired Maha Katabi as a partner. Katabi, who has worked as a Canadian venture capital and public equities professional for more than 18 years, joined from Oxalis Capital, an innovative therapeutics investor she founded in 2018. Previously, she was a partner at Sectoral Asset Management, a vice president at Ventures West Management and an associate at T2C2 Capital. With Katabi’s hire, Sofinnova said it will open an office in Montréal, enabling the firm to work more closely with companies based in the Eastern United States, Europe and Canada.
Sofinnova hires Maha Katabi as partner, will open Montréal officeSilicon Valley biotechnology investment firm Sofinnova Investments has hired Maha Katabi as a partner. Katabi, who has worked as a Canadian venture capital and public equities professional for more than 18 years, joined from Oxalis Capital, an innovative therapeutics investor she founded in 2018. Previously, she was a partner at Sectoral Asset Management, a vice president at Ventures West Management, and an associate at T2C2 Capital. With Katabi's hire, Sofinnova said it will open an office in Montréal, enabling the firm to work more closely with companies based in the Eastern United States, Europe and Canada.
- Biotech firm Inozyme fetches $67 mln
Boston-based Inozyme Pharma Inc, a biotechnology company, has raised $67 million in Series A2 financing. Pivotal bioVenture Partners and Sofinnova Investments led the round.
- Karuna Therapeutics nabs $12 mln, raising Series B to $80 mln
Karuna Therapeutics has raised an additional $12 million for its Series B round, bringing the total to $80 million. The new investor is Sofinnova Investments. Karuna focuses on targeting muscarinic cholinergic receptors for the treatment of neuropsychiatric disorders.
- VelosBio picks up $58 mln Series A
VelosBio, a biotech firm focused on oncology, has raised $58 million in Series A funding. Arix Bioscience plc and Sofinnova Ventures led the round with participation from other other investors that included Pappas Ventures, Chiesi Ventures, Takeda Ventures Inc and Decheng Capital. In conjunction with the funding, Mark Chin, Arix investment director, will join the VelosBio board of directors.